The short version
The review lists Vesilut as ED and includes computer docking to the LAT1 transporter. Docking estimates a molecular interaction; it does not measure clinical benefit or absorption in people.
An investigational profile is not an endorsement or a finding of safety.
Names you may see
Compound names, research identifiers, brand names and informal shorthand serve different purposes.
- Vesilut
- Entry name · The name used for this encyclopedia topic.
- Vesilut (ED)
- Name in the cited review · The review identifies ED; do not confuse it with the different KED peptide Vesugen.
Similar names do not establish identical ingredients, molecular variants, product quality or interchangeable preparations. A blend nickname may describe different formulas.
Things worth checking
Does predicted binding show that it works for the bladder?
No. A transport-model score is a prediction about a molecular interaction. It is not a measured bladder outcome, a human absorption study or a safety assessment.
Scope of the review and docking table · Transport of biologically active ultrashort peptides using POT and LAT carriers ↗
Questions to bring to a clinician or pharmacist
- Which findings apply to my goal and medical history?
- Could my medicines, supplements, or other compounds change the assessment?
- What monitoring, if any, would inform a decision—and what symptoms would need evaluation?
Monitoring is individual. Normal bloodwork does not establish that a compound or preparation is safe.
Clinical research
The review’s bladder-related label is not a controlled bladder-treatment result. Its docking score does not establish potency, a useful administration route or human safety.
Research terms in everyday language ↗
This is a bounded context overview, not a completed clinical literature appraisal. The linked source has the scope stated here; related-compound findings are not evidence for this preparation.
Read findings in the context of the exact product or preparation, the people studied, and the outcome measured. These draft profiles are starting points, rather than complete systematic reviews.
Community research
Structured community reports can help identify questions worth studying. They are considered separately from controlled studies, with their limitations kept visible.
No community reports published yet.
This profile has no published community dataset. We do not infer a trend or a benefit from missing reports.
How community research will work ↗What we will document about community advice
- The advice
- What people recommend, with dated sources and the scope of the discussions examined.
- The reasoning
- Why contributors believe it helps, without treating that explanation as an established mechanism.
- The evidence
- What supports the claim, contradicts it, or has not been tested.
- The cautions
- Possible downsides, conflicting experiences, and questions for a clinician or pharmacist.
No recommendation or community consensus is established by this framework. Descriptions of how common advice is will need documented source coverage.
A closer look
- Classification
- A short peptide name identified as Glu-Asp (ED) in a published peptide-transport review.
- Name variations
- Names you may see and important distinctions
- Source type
- Review with computational transport modeling · identity table checked
- Reference jurisdiction
- Research context; approval is product- and country-specific
Interpret the source in the context of the preparation and route it discusses. A regulatory notice and a controlled clinical trial answer different questions.
This first design edition reserves space for study-by-study summaries, definitions, and technical references as each profile receives editorial review.
Go to the source
Study cards identify whether the summary uses an abstract, full text, or an agency assessment. Follow the linked sources for their original context.
Source reference · Checked 8 November 2026 · Opens in a new tab
For athletes: competition rules are a separate check ↗